公开(公告)号：US20240116910A1

公开(公告)日：2024-04-11

申请号：US18368467

申请日：2023-09-14

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Binh Vu ,  Romyr Dominique ,  Yi Chen ,  Hongju Li

IPC: C07D409/12 ,  C07D277/28 ,  C07D333/22 ,  C07D409/04 ,  C07D409/14 ,  C07D417/12 ,  C07D487/04

CPC classification number: C07D409/12 ,  C07D277/28 ,  C07D333/22 ,  C07D409/04 ,  C07D409/14 ,  C07D417/12 ,  C07D487/04

Abstract: The present disclosure relates to the use of substituted heterocycles for the inhibition of the activity of WIP1. Suitably, the present disclosure relates to the use of substituted heterocycles for the treatment of cancer.

公开(公告)号：US11731953B2

公开(公告)日：2023-08-22

申请号：US17354203

申请日：2021-06-22

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Binh Vu ,  Romyr Dominique ,  Hongju Li ,  Bruce Fahr ,  Yi Chen

IPC: C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D209/46 ,  C07D209/94 ,  C07D209/34

CPC classification number: C07D401/04 ,  C07D209/34 ,  C07D209/46 ,  C07D209/94 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

公开(公告)号：US11926632B2

公开(公告)日：2024-03-12

申请号：US17353199

申请日：2021-06-21

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Binh Vu ,  Romyr Dominique ,  Hongju Li ,  Bruce Fahr ,  Yi Chen

IPC: C07D487/10 ,  C07C237/40 ,  C07D213/36 ,  C07D213/38 ,  C07D213/73 ,  C07D213/81 ,  C07D215/12 ,  C07D231/56 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D487/08 ,  C07D491/107

CPC classification number: C07D487/10 ,  C07C237/40 ,  C07D213/36 ,  C07D213/38 ,  C07D213/73 ,  C07D213/81 ,  C07D215/12 ,  C07D231/56 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D487/08 ,  C07D491/107

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

公开(公告)号：US20230046427A1

公开(公告)日：2023-02-16

申请号：US17353199

申请日：2021-06-21

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Binh Vu ,  Romyr Dominique ,  Hongju Li ,  Bruce Fahr ,  Yi Chen

IPC: C07D487/10 ,  C07D213/36 ,  C07D401/12 ,  C07D213/73 ,  C07D231/56 ,  C07C237/40 ,  C07D239/42 ,  C07D405/12 ,  C07D213/81 ,  C07D417/12 ,  C07D413/12 ,  C07D487/08 ,  C07D491/107

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.